Lubrizol Life Science Health — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Lubrizol Life Science Health operates as a critical enabler within the global healthcare supply chain, specializing in advanced polymer-based technologies for drug delivery and medical devices. As a division of the publicly-traded Lubrizol Corporation, it provides formulation expertise, excipients, and material science solutions to pharmaceutical, biotech, and medical device companies. Its business model is B2B, offering platform technologies and services that help partners bring more effective and patient-friendly products to market. With a long history since 1928, the division combines deep material science knowledge with regulatory experience to address complex healthcare challenges.

Drug DeliveryMedical Devices

Technology Platform

Advanced polymer science for drug delivery systems (e.g., controlled release, bioavailability enhancement) and medical device components (e.g., biocompatible thermoplastic polyurethanes).

Funding History

1

UndisclosedUndisclosedLubrizol CorporationJun 15, 2021

Opportunities

The growing pipeline of poorly soluble drugs creates sustained demand for advanced formulation and drug delivery solutions.

Expansion into new therapeutic modalities (e.g., mRNA, cell therapy) and geographic markets, particularly in Asia, presents significant growth potential.

The trend towards patient-centric, non-invasive drug delivery and more complex medical devices drives need for sophisticated polymer technologies.

Risk Factors

Revenue is dependent on the success and regulatory approval of partner products, creating indirect pipeline risk.

Intense competition from other advanced material suppliers and potential commoditization of some excipient products could pressure margins.

Regulatory changes across global markets could alter approval pathways for drugs and devices using Lubrizol's components, impacting time-to-market for partners.

Competitive Landscape

Lubrizol competes with other large specialty chemical and life science companies such as BASF, Ashland, Dow Chemical, and Evonik in the pharmaceutical excipients and drug delivery space. In medical device polymers, it faces competition from companies like DSM, Covestro, and Solvay. Its competitive edge lies in its deep polymer science heritage, broad portfolio, and integrated formulation and regulatory support services.

More companies in Drug Delivery & Formulation →More companies in United States →